Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.56 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR2B | P41595 | 4/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835145 | 1.00 | PNMT (0.56) | PNMTASIC3TDP2CHRNB2CHRNA4 | |
| Bromide SCHEMBL2310632 | 0.98 | PNMT (0.54) | PNMTASIC3TDP2CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL29627981 | 0.98 | PNMT (0.54) | PNMTASIC3TDP2CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL1647036 | 0.98 | PNMT (0.54) | PNMTASIC3TDP2CHRNB2CHRNA4 | |
| Bromide SCHEMBL2310627 | 0.96 | PNMT (0.53) | PNMTASIC3TDP2CHRNB2CHRNA4 | |
| SCHEMBL4820420 | 0.87 | PNMT (0.56) | PNMTASIC3TDP2CHRNB2CHRNA4 | |
| SCHEMBL183621 | 0.84 | ASIC3 (0.60) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL329770 | 0.84 | ASIC3 (0.69) | PNMTASIC3HTR2AHTR2CHTR2B | |
| SCHEMBL29808272 | 0.84 | ASIC3 (0.60) | PNMTASIC3HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL1000104 | 0.83 | ASIC3 (0.68) | PNMTASIC3HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336603-A1 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2024-10-10 | — | — | US | claimed |
| WO-2022269134-A1 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2022-12-29 | — | — | WO | claimed |
| EP-4692079-A1 | CYP11A1 INHIBITOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024217531-A1 | CYP11A1 INHIBITORS AND USE THEREOF | 西藏海思科制药有限公司 | 2024-10-24 | — | — | WO | disclosed |
| US-20240336603-A1 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2024-10-10 | — | — | US | disclosed |
| US-20240336603-A1 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2024-10-10 | — | — | US | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024199262-A1 | CYP11A1 INHIBITOR AND USE THEREOF | 西藏海思科制药有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| EP-4359384-A1 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2024-05-01 | — | — | EP | disclosed |
| US-11858900-B2 | Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives | OCUTERRA THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-7482336-B2 | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2009-01-27 | — | — | US | disclosed |
| CN-100434420-C | Compounds that block dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO (JP) | 2008-11-19 | — | — | CN | disclosed |
| US-7345180-B2 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20070254865-A1 | 2-substituted phenyl-5-fused heteroaryl cyclohexylamines; may be coadministered with metformin; non-insulin dependent diabetes | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| CN-1745063-A | Compound inhibiting dipeptidyl peptidase iv | SANWA KAGAKU KENKYUSHO CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| EP-1595866-A1 | COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV | Sanwa Kagaku Kenkyusho Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336603-A1 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | CYP11B1, CYP4A11, CYP19A1 | PNMT 1364/4885ASIC3 4749/4885TDP2 3723/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | PNMT 3565/4885ASIC3 4787/4885TDP2 4681/4885 |
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | PNMT 4767/4885ASIC3 4146/4885TDP2 1147/4885 |
| US-11858900-B2 | Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives | KCNQ2, KCNQ1, KCNQ3 | PNMT 969/4885ASIC3 102/4885TDP2 1880/4885 |
| US-20070254865-A1 | 2-substituted phenyl-5-fused heteroaryl cyclohexylamines; may be coadministered with metformin; non-insulin dependent diabetes | DPP4, DPP3, DPP7 | PNMT 353/4885ASIC3 2633/4885TDP2 902/4885 |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | DPP4, DPP3, DPP7 | PNMT 2888/4885ASIC3 1772/4885TDP2 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.